Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness-Reference-Cited by-同舟云学术

Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness

Published:2024-08 Issue: Volume: Page:114266
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Zhang Pei,Han Yihui,Cai Zhaolun,Cao Dan

Funder

Sichuan University

Sichuan University West China Hospital

Publisher

Elsevier BV

Reference8 articles.

1. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness;Yoshino;Eur J Cancer,2024

2. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group;Bond;Lancet Oncol,2023

3. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial;Heinemann;Br J Cancer,2021

4. 468P PANIB 20139173: Randomized, multicentre phase II trial comparing fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus panitumumab versus FOLFOX plus bevacizumab in patients with previously untreated, RAS wild-type (WT) metastatic colorectal cancer (mCRC)

5. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial;Watanabe;Jama,2023